12:00 AM
 | 
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Taxotere docetaxel: Phase III data; marketed to treat locally advanced or metastatic breast cancer after failure of prior chemotherapy

In a 429-patient Phase III trial, time to disease progression was 37 weeks for patients treated with docetaxel plus doxorubicin compared to 32 weeks for...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >